Biologics CDMO Market Share

Statistics for the 2023 & 2024 Biologics CDMO market share, created by Mordor Intelligence™ Industry Reports. Biologics CDMO share report includes a market forecast to 2029 and historical overview. Get a sample of this industry share analysis as a free report PDF download.

Single User License
Team License
Corporate License
Book before:

Single User License

OFF

Team License

OFF

Corporate License

OFF
Book before:

Market Share of Biologics CDMO Industry

The biologics contract development and manufacturing organization (CDMO) market is highly concentrated, with close to half of the market being dominated by a few players. In 2021, major players, such as Catalent, Boehringer Ingelheim Group, Lonza Group, and Samsung Biologics, together accounted for more than 30.1% of the market studied.

  • May 2022 - Euroapi is a CDMO specializing in small-molecule active pharmaceutical ingredients (APIs). In May 2022, the company's stock began trading on the Euronext Paris stock exchange. Sanofi is extending its support for the CDMO by establishing a long-term customer relationship with Euroapi. It has agreed to hold a minority stake of approximately 30% in the CDMO for a two-year lock-up period. Furthermore, EPIC Bpifrance, a French public investment bank owned by the French government, has agreed to buy 12% of EuroAPI's shares from Sanofi.
  • April 2022 - ChimeronBio announced that it had signed a manufacturing agreement with FUJIFILM DiosynthBiotechnologies (FDB) to advance its Oncology portfolio to include clinics. ChimeronBio opted for FUJIFILM DiosynthBiotechnologies as its partner for transferring and scaling its drug substance manufacturing process.
  • January 2022 - Samsung Biologics signed an agreement with Biogen to acquire Biogen's 50% stake in Samsung Bioepis, a joint venture formed by the two companies, for up to USD 2.3 billion. The complete buyout of Biogen's stake by Samsung Biologics is anticipated to strengthen Samsung Bioepis' biosimilar development capabilities and future performance in new drug development.

Biologics Contract Development & Manufacturing Organization (CDMO) Market Leaders

  1. Boehringer Ingelheim Group

  2. Wuxi Biologics

  3. Samsung Biologics

  4. Lonza Group

  5. Fujifilm Diosynth Biotechnologies USA Inc.

*Disclaimer: Major Players sorted in no particular order

Biologics CDMO Market Concentration

Biologics CDMO Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)